Reports Fourth-Quarter Total Revenues of $3.7B and Full-Year 2025 Total Revenues of $14.3B Meets or Exceeds 2025 Financial Guidance Across All Key Metrics[1] Returns More Than $1B to Shareholders...

Viatris Inc. (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will...

Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS)...

Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today...

Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly...

Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR Depot (Octreotide Acetate for Injectable Suspension) U.S. FDA Accepts New Drug Application for...